Albendazole


Full Generic Medicine Info
Dosage/Direction for Use

Oral
Echinococcosis
Adult: <60 kg: 15 mg/kg daily in 2 divided doses. Max: 800 mg daily. ≥60 kg: 400 mg bid. Administer doses for 28-day cycle followed by a 14-day drug-free interval for a total of 3 cycles.
Child: Same as adult dose.

Oral
Neurocysticercosis
Adult: <60 kg: 15 mg/kg daily in 2 divided doses. Max: 800 mg daily. ≥60 kg 400 mg bid. Duration of treatment: 8-30 days.
Child: Same as adult dose.

Oral
Enterobiasis
Adult: 400 mg as a single dose.
Child: 1-2 years 200 mg as a single dose. 2 years Same as adult dose. Max: 200 mg.

Oral
Hookworm infections
Adult: 400 mg as a single dose.
Child: 1-2 years 200 mg as a single dose. 2 years Same as adult dose. Max: 200 mg.

Oral
Trichuriasis
Adult: 400 mg as a single dose.
Child: 1-2 years 200 mg as a single dose. 2 years Same as adult dose. Max: 200 mg.

Oral
Ascariasis
Adult: 400 mg as a single dose.
Child: 1-2 years 200 mg as a single dose. 2 years Same as adult dose. Max: 200 mg.

Oral
Tapeworm infections
Adult: 400 mg daily for 3 consecutive days. Max: 400 mg daily; 1,200 mg for 3 days. If patient is not cured after 3 weeks, a second course of treatment is needed. In cases of Hymenolepis nana infestations, retreatment in 10-21 days is recommended. Administration information may vary between countries and individual products.
Child: >2 years Same as adult dose

Oral
Clonorchiasis
Adult: 400 mg bid for 3 days. Max: 800 mg daily; 1,200 mg for 3 days. Confirm with your doctor after 1 month if worms have been eradicated.
Child: >2 years Same as adult dose.

Oral
Opisthorchiasis
Adult: 400 mg bid for 3 days. Max: 800 mg daily; 1,200 mg for 3 days. Confirm with your doctor after 1 month if worms have been eradicated.
Child: >2 years Same as adult dose.

Oral
Cutaneous larva migrans
Adult: 400 mg once daily for 1-3 days. Max: 400 mg daily; 1,200 mg for 3 days.
Child: >2 years Same as adult dose.

Oral
Giardiasis
Child: 1-12 years 400 mg once daily for 5 days. Max: 400 mg daily; 2, 000 mg for 5 days. Administration information may vary between countries and individual products.
Administration
Should be taken with food.
Contraindications
Hypersensitivity. Pregnancy.
Special Precautions
Patient with neurocysticercosis, retinal lesions. May cause inflammatory reaction within the brain. Increased risk of bone marrow suppression in patient with liver disease. Hepatic impairment. Lactation. Patient Counselling This drug may cause dizziness, if affected, do not drive or operate machinery. Maintain strict hygiene. Monitoring Parameters Monitor LFT and CBC with differential at start of each 28-day cycle and every 2 weeks during therapy. Assess faecal specimens for ova and parasites for 3 weeks after treatment. Obtain baseline ophthalmic exam for retinal lesions. Monitor for cerebral hypertension, focal neurologic deficits, or seizures after initiation of therapy and obtain pregnancy test during treatment.
Adverse Reactions
Blood and lymphatic system disorders: Leukopenia, neutropenia. Eye disorders: Blurred vision. Gastrointestinal disorders: Abdominal pain, nausea, vomiting, diarrhoea. General disorders and administration site conditions: Fever, asthenia. Hepatobiliary disorders: Mild to moderate hepatic enzyme elevation, hepatitis, acute liver failure. Musculoskeletal and connective tissue disorders: Rhabdomyolysis. Nervous system disorders: Headache, dizziness, somnolence, convulsion. Renal and urinary disorders: Acute renal failure. Skin and subcutaneous tissue disorders: Itchiness, alopecia, erythema multiforme, Stevens-Johnson syndrome.
Potentially Fatal: Hypersensitivity reactions e.g. rash, pruritus, urticaria; bone marrow suppression, granulocytopenia, pancytopenia, aplastic anaemia, agranulocytosis.
Drug Interactions
May increase plasma concentration with cimetidine, dexamethasone and praziquantel. May decrease serum concentrations with carbamazepine, ritonavir, phenobarbital, and phenytoin.
Food Interaction
Increased serum concentrations with a fatty meal. May increase serum concentrationswith grapefruit or grapefruit juice.
Action
Albendazole, a benzimidazole derivative, is an anthelmintic that inhibits microtubule formation by binding to colchicine sensitive site of β-tubulin resulting to decrease in microtubules leading to decline in glucose uptake and absorptive function and depletion of glycogen storage by adult and larval forms of parasites. Insufficient glucose causes lack of ATP resulting to death of parasite.
Absorption: Poorly absorbed in the gastrointestinal tract. Increased serum concentration with a fatty meal. Time to peak serum concentration: 2-5 hours for the metabolite.
Distribution: Widely distributed throughout the body including urine, bile, liver, cyst wall, cyst fluid and CSF. Enters breast milk. Plasma protein binding: 70%.
Metabolism: Undergoes extensive hepatic first pass metabolism via rapid sulfoxidation to albendazole sulphoxide (primary metabolite).
Excretion: Via urine (<1% as active metabolite); faeces. Elimination half-life: 8-12 hours (albendazole sulphoxide).
Storage
Oral: Store between 20-25°C. Protect from light.
CIMS Class
ATC Classification
P02CA03 - albendazole ; Belongs to the class of benzimidazole derivative agents. Used as antinematodal.
Disclaimer: This information is independently developed by CIMS based on albendazole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
MORE
LESS
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in